ArticleThe oncologist2026
Genomic determinants and an exploratory prognostic model for immunotherapy outcomes in recurrent or metastatic cervical cancer.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundImmune checkpoint inhibitors (ICIs) improve outcomes in recurrent or metastatic cervical cancer, but responses are heterogeneous and biomarkers beyond programmed death-ligand 1 (PD-L1) are limited. MATERIALS AND
methodsTargeted sequencing of 437 cancer-related genes was performed in 42 patients receiving ICI-based therapy. Genomic correlates of progression-free survival (PFS) were evaluated, and an exploratory prognostic model was developed using least absolute shrinkage and selection operator regression and multivariable Cox regression. The Cancer Genome Atlas (TCGA) cohort was used for transcriptomic analysis.
resultsThe cohort included 42 patients, with a median age of 51 years; 85.7% were human papillomavirus-positive, 90.5% had squamous cell carcinoma, and 54.8% had a programmed death-ligand 1 combined positive score (PD-L1 CPS) ≥5. Frequent alterations included PIK3CA (57.1%), FBXW7 (21.4%), TERT (21.4%), BAP1 (19.0%), and EP300 (16.7%). Tumor mutational burden-associated mutations in PIK3CA, EP300, CREBBP, and TERT were associated with prolonged PFS (P < .001), whereas PD-L1-associated mutations showed numerically longer PFS (P = .170). EP300 (P = .007), PIK3CA (P < .01), and homologous recombination repair pathway alterations (P = .016) were associated with favorable PFS, whereas KEAP1 (P < .01) and TP53 (P = .010) mutations were associated with shorter PFS. A five-feature genomic model stratified patients into high- and low-risk groups (P < .001, 1-year AUC = .889). In the exploratory cohort, high-risk patients showed numerically shorter PFS (P = .060). In TCGA samples, high-risk tumors showed enrichment of angiogenesis, epithelial-mesenchymal transition, hypoxia, inflammatory response, and tumor necrosis factor-α/nuclear factor-κB signaling.
conclusionSpecific genomic alterations may help stratify immunotherapy outcomes in recurrent or metastatic cervical cancer. The proposed genomic risk model remains exploratory and requires validation in larger, independent cervical cancer cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.